THERATECH

Theratechnologies is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies... Theratechnologies was founded in 1993 and currently employs more than 100 people in Canada, the United States and Europe. Headquartered in Montreal, Quebec (Canada), Theratechnologies commercializes two medicines in HIV and has research programs in HIV, NASH and Oncology... Theratechnologies is leveraging its SORT1+ Technology™ to develop a new class of therapy that targets sortilin (SORT1)-positive cancers by linking anticancer drugs to proprietary peptides that specifically bind to the sortilin receptor. TH1902, the leading product candidate derived from the SORT1+ Technology, is a first-in-class peptide-drug conjugate (PDC) that targets the sortilin receptor. In 2021, the FDA granted a Fast-Track Designation to TH1902 for developmentas a single agent for the treatment of patients with sortilin-positive recurrent advanced solid tumors that are..

Also known as: Theratechnologies, Theratechnologies Europe Limited, Theratechnologies Inc., Theratechnologies U.S., Inc.

Primary location: Québec Canada